

8. Reduction in anti-PM response




FIGURE 1




FIGURE 2

005 001 00000000




FIGURE 4

006037-6600450





FIGURE 5



BAHA_{ox}-EDDA

- 11-I, PN = (CA)₁₀
11-II, PN = (CA)₁₀·(TG)₁₀
11-IV, PN = (CA)₈·(TG)₈
11-VI, PN = (CA)₁₂·(TG)₁₂
11-VIII, PN = (CA)₁₆·(TG)₁₆

FIGURE 6A






FIGURE 6B

000001 000002 000003 000004 000005 000006 000007 000008 000009 000010 000011 000012 000013 000014 000015 000016 000017 000018 000019 000020 000021 000022 000023 000024 000025 000026 000027 000028 000029 000030 000031 000032 000033 000034 000035 000036 000037 000038 000039 000040 000041 000042 000043 000044 000045 000046 000047 000048 000049 000050 000051 000052 000053 000054 000055 000056 000057 000058 000059 000060

T Cell Proliferation Induced by Mellitin Peptides




FIGURE 8

IgG serum circulating Ab to melittin peptide 2




FIGURE 9

005217 663260

IgG serum circulating levels to Melittin




FIGURE 10

RELATIVE NUMBER OF ANTIBODY FORMING CELLS

150

100

50

0

FORMULATION BUFFER (CONTROL)

CONJUGATE 2

TREATMENT

Treatment	Relative Number of Antibody Forming Cells (approx.)
Formulation Buffer (Control)	100
Conjugate 2	20

FIGURE 11

O.D. 450 nm

IgG serum circulating Ab to Peptide 5






FIGURE 12

Melittin Peptide Conjugates



Melittin Conjugate # 1, R = H₂N-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-Lys-Cys-Gly-CO₂H

Average n = approx. 74



Melittin Conjugate # 2, R = H₂N-Cys-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-Gly-CO₂H

Melittin Conjugate # 3, R = H₂N-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-Lys-Cys-Gly-CO₂H


Melittin Conjugate # 4, R = H₂N-Cys-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-Gly-CO₂H

Melittin Conjugate # 5, R = (H₂N-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln)₂-Lys-Cys-Gly-CO₂H

Melittin peptides attached through sulfur atom on added cysteine, average n = approx. 74

FIGURE 13

Inhibition of Anti-ds^{PN} by LJP- 249 and LJP- 105



● LJP- 249 A + LJP- 249 B ▲ LJP- 105

FIGURE 14

006327-6633460

Treatment of Male BXSB Mice with LJP394




FIGURE 15